These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 23582055)

  • 21. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection.
    Duell BL; Carey AJ; Tan CK; Cui X; Webb RI; Totsika M; Schembri MA; Derrington P; Irving-Rodgers H; Brooks AJ; Cripps AW; Crowley M; Ulett GC
    J Immunol; 2012 Jan; 188(2):781-92. PubMed ID: 22184725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli.
    Hunstad DA; Justice SS
    Annu Rev Microbiol; 2010; 64():203-21. PubMed ID: 20825346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coping with a stressful host.
    Thumbikat P
    Virulence; 2011; 2(3):175-6. PubMed ID: 21597321
    [No Abstract]   [Full Text] [Related]  

  • 24. Uropathogenic Escherichia coli as a model of host-parasite interaction.
    Svanborg C; Bergsten G; Fischer H; Godaly G; Gustafsson M; Karpman D; Lundstedt AC; Ragnarsdottir B; Svensson M; Wullt B
    Curr Opin Microbiol; 2006 Feb; 9(1):33-9. PubMed ID: 16406777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bactofection with toll-like receptor 4 in a murine model of urinary tract infection.
    Tóthová L; Hodosy J; Kamodyová N; Janega P; Slobodníková L; Liptáková A; Boor P; Celec P
    Curr Microbiol; 2011 Jun; 62(6):1739-42. PubMed ID: 21442393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The classical complement pathway plays a critical role in the opsonisation of uropathogenic Escherichia coli.
    Li K; Sacks SH; Sheerin NS
    Mol Immunol; 2008 Feb; 45(4):954-62. PubMed ID: 17870166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacterial virulence factors are associated with occurrence of acute pyelonephritis but not renal scarring.
    Chiou YY; Chen MJ; Chiu NT; Lin CY; Tseng CC
    J Urol; 2010 Nov; 184(5):2098-102. PubMed ID: 20850815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli.
    Billips BK; Yaggie RE; Cashy JP; Schaeffer AJ; Klumpp DJ
    J Infect Dis; 2009 Jul; 200(2):263-72. PubMed ID: 19522648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microcins and urovirulence in Escherichia coli.
    Azpiroz MF; Poey ME; Laviña M
    Microb Pathog; 2009 Nov; 47(5):274-80. PubMed ID: 19744552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCAAT/enhancer-binding protein delta activates the Runx2-mediated transcription of mouse osteocalcin II promoter.
    Shin CS; Jeon MJ; Yang JY; Her SJ; Kim D; Kim SW; Kim SY
    J Mol Endocrinol; 2006 Jun; 36(3):531-46. PubMed ID: 16720721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of uropathogenic Escherichia coli with host uroepithelium.
    Kau AL; Hunstad DA; Hultgren SJ
    Curr Opin Microbiol; 2005 Feb; 8(1):54-9. PubMed ID: 15694857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infection: Uropathogenic Escherichia coli get a return TRP.
    Thoma C
    Nat Rev Urol; 2015 Jul; 12(7):362. PubMed ID: 26077998
    [No Abstract]   [Full Text] [Related]  

  • 33. CXC chemokine receptor 2 contributes to host defense in murine urinary tract infection.
    Olszyna DP; Florquin S; Sewnath M; Branger J; Speelman P; van Deventer SJ; Strieter RM; van der Poll T
    J Infect Dis; 2001 Aug; 184(3):301-7. PubMed ID: 11443555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The inhibitory receptor CD300a is essential for neutrophil-mediated clearance of urinary tract infection in mice.
    Isaacson B; Baron M; Yamin R; Bachrach G; Levi-Schaffer F; Granot Z; Mandelboim O
    Eur J Immunol; 2021 Sep; 51(9):2218-2224. PubMed ID: 34268737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting the Escherichia coli polysaccharide capsule as a virulence factor during urinary tract infection: contribution to intracellular biofilm development.
    Goller CC; Seed PC
    Virulence; 2010; 1(4):333-7. PubMed ID: 21178466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of vitamin D on the innate immune response to uropathogenic Escherichia coli during pregnancy.
    Ramos NL; Sekikubo M; Kironde F; Mirembe F; Sääf M; Brauner A
    Clin Microbiol Infect; 2015 May; 21(5):482.e1-7. PubMed ID: 25640157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uropathogenic Escherichia coli causes cortical tubular necrotic cell death and the release of macrophage migration inhibitory factor.
    Hong MY; Tseng CC; Chuang CC; Chen CL; Lin YH; Hsieh CY; Chang YT; Hsing CH; Chang KY; Lin CF
    Cytokine; 2013 Mar; 61(3):945-52. PubMed ID: 23410506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CTX-M-32 beta-lactamase-producing uropathogenic Escherichia coli isolated in Latin America.
    Araque M; Millán B; Mendoza E; Salas M
    J Infect Dev Ctries; 2013 May; 7(5):432-5. PubMed ID: 23669435
    [No Abstract]   [Full Text] [Related]  

  • 39. Structure-based virtual screening for plant-derived SdiA-selective ligands as potential antivirulent agents against uropathogenic Escherichia coli.
    Ravichandiran V; Shanmugam K; Anupama K; Thomas S; Princy A
    Eur J Med Chem; 2012 Feb; 48():200-5. PubMed ID: 22209416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary tract infections in renal transplant recipients: virulence traits of uropathogenic Escherichia coli.
    Merçon M; Regua-Mangia AH; Teixeira LM; Irino K; Tuboi SH; Goncalves RT; Santoro-Lopes G
    Transplant Proc; 2010 Mar; 42(2):483-5. PubMed ID: 20304171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.